The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Somatic mutations in DROSHA and DICER1 impair microRNA biogenesis through distinct mechanisms in Wilms tumours
Open accessAbstract
Wilms tumour is the most common childhood kidney cancer. Here we report the whole-exome sequencing of 44 Wilms tumours, identifying missense mutations in the microRNA (miRNA)-processing enzymes DROSHA and DICER1, and novel mutations in MYCN, SMARCA4 and ARID1A. Examination of tumour miRNA expression, in vitro processing assays and genomic editing in human cells demonstrates that DICER1 and DROSHA mutations influence miRNA processing through distinct mechanisms. DICER1 RNase IIIB mutations preferentially impair processing of miRNAs deriving from the 5′-arm of pre-miRNA hairpins, while DROSHA RNase IIIB mutations globally inhibit miRNA biogenesis through a dominant-negative mechanism. Both DROSHA and DICER1 mutations impair expression of tumour-suppressing miRNAs, including the let-7 family, important regulators of MYCN, LIN28 and other Wilms tumour oncogenes. These results provide new insights into the mechanisms through which mutations in miRNA biogenesis components reprogramme miRNA expression in human cancer and suggest that these defects define a distinct subclass of Wilms tumours. Wilms tumour is a common childhood cancer. Here, the authors use whole-exome sequencing in 44 Wilms tumours to characterize their mutational landscape and show that DICER1 and DROSHAmutations can suppress the biogenesis of tumour-suppressing microRNAs.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The widespread regulation of microRNA biogenesis, function and decay
Krol, J., Loedige, I., & Filipowicz, W. (2010) · Nature Reviews Genetics · doi:10.1038/nrg2843 · Cited by 4,672
Driver mutations in histone H3.3 and chromatin remodelling genes in paediatric glioblastoma
Schwartzentruber, J., Korshunov, A., Liu, X.-Y., Jones, D. T. W., Pfaff, E., Jacob, K., Sturm, D., Fontebasso, A. M., Quang, D.-A. K., Tönjes, M., et al. (2012) · Nature · doi:10.1038/nature10833 · Cited by 2,631
DICER1 Mutations in Familial Pleuropulmonary Blastoma
Hill, D. A., Ivanovich, J., Priest, J. R., Gurnett, C. A., Dehner, L. P., Desruisseau, D., Jarzembowski, J. A., Wikenheiser-Brokamp, K. A., Suarez, B. K., Whelan, A. J., et al. (2009) · Science · doi:10.1126/science.1174334 · Cited by 751
Cited by
MicroRNA therapeutics: towards a new era for the management of cancer and other diseases
Rupaimoole, R., & Slack, F. J. (2017) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2016.246 · Cited by 4,741
MicroRNA biogenesis pathways in cancer
Lin, S., & Gregory, R. I. (2015) · Nature Reviews Cancer · doi:10.1038/nrc3932 · Cited by 2,112
The COSMIC Cancer Gene Census: describing genetic dysfunction across all human cancers
Sondka, Z., Bamford, S., Cole, C. G., Ward, S. A., Dunham, I., & Forbes, S. A. (2018) · Nature Reviews Cancer · doi:10.1038/s41568-018-0060-1 · Cited by 1,597
Regulation of microRNA biogenesis and its crosstalk with other cellular pathways
Treiber, T., Treiber, N., & Meister, G. (2019) · Nature Reviews Molecular Cell Biology · doi:10.1038/s41580-018-0059-1 · Cited by 1,252
A network-biology perspective of microRNA function and dysfunction in cancer
Bracken, C. P., Scott, H. S., & Goodall, G. J. (2016) · Nature Reviews Genetics · doi:10.1038/nrg.2016.134 · Cited by 668
A Children's Oncology Group and TARGET initiative exploring the genetic landscape of Wilms tumor
Gadd, S., Huff, V., Walz, A. L., Ooms, A. H. A. G., Armstrong, A. E., Gerhard, D. S., Smith, M. A., Guidry Auvil, J. M., Meerzaman, D., Chen, Q.-R., et al. (2017) · Nature Genetics · doi:10.1038/ng.3940 · Cited by 367
Uncovering novel mutational signatures by de novo extraction with SigProfilerExtractor
Islam, S. M. A., Díaz-Gay, M., Wu, Y., Barnes, M., Vangara, R., Bergstrom, E. N., He, Y., Vella, M., Wang, J., Teague, J. W., et al. (2022) · Cell Genomics · doi:10.1016/j.xgen.2022.100179 · Cited by 365
miRNA: A Promising Therapeutic Target in Cancer
Menon, A., Abd-Aziz, N., Khalid, K., Poh, C. L., & Naidu, R. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms231911502 · Cited by 357
Wegert, J., Ishaque, N., Vardapour, R., Geörg, C., Gu, Z., Bieg, M., Ziegler, B., Bausenwein, S., Nourkami, N., Ludwig, N., et al. (2015) · Cancer Cell · doi:10.1016/j.ccell.2015.01.002 · Cited by 302
The genetic changes of Wilms tumour
Treger, T. D., Chowdhury, T., Pritchard-Jones, K., & Behjati, S. (2019) · Nature Reviews Nephrology · doi:10.1038/s41581-019-0112-0 · Cited by 257
Genome-wide annotation of microRNA primary transcript structures reveals novel regulatory mechanisms
Chang, T.-C., Pertea, M., Lee, S., Salzberg, S. L., & Mendell, J. T. (2015) · Genome Research · doi:10.1101/gr.193607.115 · Cited by 103
Self-citationGenomic imbalances pinpoint potential oncogenes and tumor suppressors in Wilms tumors
Krepischi, A. C. V., Maschietto, M., Ferreira, E. N., Silva, A. G., Costa, S. S., da Cunha, I. W., Barros, B. D. F., Grundy, P. E., Rosenberg, C., & Carraro, D. M. (2016) · Molecular Cytogenetics · doi:10.1186/s13039-016-0227-y · Cited by 56
MicroRNA and Rare Human Diseases
Goel, H., & Goel, A. (2024) · Genes · doi:10.3390/genes15101243 · Cited by 21
Constitutive Dicer1 phosphorylation accelerates metabolism and aging in vivo
Aryal, N. K., Pant, V., Wasylishen, A. R., Parker-Thornburg, J., Baseler, L., El-Naggar, A. K., Liu, B., Kalia, A., Lozano, G., & Arur, S. (2019) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1814377116 · Cited by 18
Dicer1 phosphomimetic promotes tumor progression and dissemination
Aryal, N. K., Pant, V., Wasylishen, A. R., Rimel, B. J., Baseler, L., El-Naggar, A. K., Mutch, D. G., Goodfellow, P. J., Arur, S., & Lozano, G. (2019) · Cancer Research · doi:10.1158/0008-5472.can-18-2460 · Cited by 17
Metadata
- Authors
- Rakheja, D., Chen, K. S., Liu, Y., Shukla, A. A., Schmid, V., Chang, T.-C., Khokhar, S., Wickiser, J. E., Karandikar, N. J., Malter, J. S., Mendell, J. T., & Amatruda, J. F.
- Venue
- Nature Communications
- Published
- 2014-09-05
- Volume
- 5
- Issue
- 1
- Pages
- 4802-4802
- ISSN
- 2041-1723 (ISSN-L)
- OpenAlex
- W2082904471
- Cited by
- 236
- References
- 3
- FWCI
- 6.32
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.